Maynard Um
-
-
-
-
-
-
-
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
-
-
-
-
-
-
-
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
-
-
-
-
-
-
-
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
-
-
-
-
-
-
-
Phio Pharmaceuticals Corp. (PHIO) Misses Q1 EPS by 34c
-
-
-
-
-
-
-
Phio Pharmaceuticals to present PH-762 cancer study results at dermatology meeting
-
-
-
-
-
-
-
Phio reports positive safety data for PH-762 skin cancer treatment
-
-
-
-
-
-
-
Phio Pharmaceuticals reports 70% response rate in skin cancer trial
-
468,764 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


